Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC

(AGN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Allergan : Form 8.3 - Allergan Plc

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/08/2019 | 09:47am EST
TIDM0Y7T TIDM0QCV 
 
 
   FORM 8.3 
 
   IRISH TAKEOVER PANEL 
 
   DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, 
TAKEOVER RULES, 2013 
 
   DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 
1% OR MORE 
 
   1. KEY INFORMATION 
 
 
 
 
Name of person dealing (Note 1)                State Street Global Advisors & 
                                               Affiliates 
---------------------------------------------  ------------------------------- 
Company dealt in                               Allergan plc 
---------------------------------------------  ------------------------------- 
Class of relevant security to which            US$0.0001 ordinary shares 
 the dealings being disclosed relate (Note 2) 
---------------------------------------------  ------------------------------- 
Date of dealing                                07(th) November 2019 
---------------------------------------------  ------------------------------- 
 
 
 
   2. INTERESTS AND SHORT POSITIONS 
 
   (a) Interests and short positions (following dealing) in the class of 
relevant security dealt in (Note 3) 
 
 
 
 
                                               Long             Short 
-------------------------------------  --------------------  ----------- 
                                         Number      (%)     Number  (%) 
-------------------------------------  ----------  --------  ------  --- 
(1) Relevant securities                15,271,401  4.65417% 
-------------------------------------  ----------  --------  ------  --- 
(2) Derivatives (other than options)          N/A 
-------------------------------------  ----------  --------  ------  --- 
(3) Options and agreements to 
 purchase/sell                                N/A 
-------------------------------------  ----------  --------  ------  --- 
Total                                  15,271,401  4.65417% 
-------------------------------------  ----------  --------  ------  --- 
 
 
   (b) Interests and short positions in relevant securities of the company, 
other than the class dealt in (Note 3) 
 
 
 
 
Class of relevant security:                     Long         Short 
-------------------------------------------  -----------  ----------- 
                                             Number  (%)  Number  (%) 
-------------------------------------------  ------  ---  ------  --- 
(1) Relevant securities                       N/A 
-------------------------------------------  ------  ---  ------  --- 
(2) Derivatives (other than options)          N/A 
-------------------------------------------  ------  ---  ------  --- 
(3) Options and agreements to purchase/sell   N/A 
-------------------------------------------  ------  ---  ------  --- 
Total                                         N/A 
-------------------------------------------  ------  ---  ------  --- 
 
 
   3. DEALINGS (Note 4) 
 
   (a) Purchases and sales 
 
 
 
 
Purchase/sale   Number of relevant securities  Price per unit (Note 5) 
--------------  -----------------------------  ----------------------- 
   Purchase                                83                   178.24 
--------------  -----------------------------  ----------------------- 
   Purchase                               736                   178.68 
--------------  -----------------------------  ----------------------- 
   Purchase                                48                   178.68 
--------------  -----------------------------  ----------------------- 
   Purchase                               154                   178.68 
--------------  -----------------------------  ----------------------- 
     Sale                              14,972                   178.68 
--------------  -----------------------------  ----------------------- 
     Sale                              50,046                   178.68 
--------------  -----------------------------  ----------------------- 
 
 
   (b) Derivatives transactions (other than options transactions) 
 
 
 
 
Product name,  Nature of transaction  Number of relevant securities  Price per unit 
 e.g. CFD       (Note 6)               (Note 7)                       (Note 5) 
-------------  ---------------------  -----------------------------  -------------- 
N/A 
-------------  ---------------------  -----------------------------  -------------- 
 
 
 
   (c) Options transactions in respect of existing relevant securities 
 
   (i) Writing, selling, purchasing or varying 
 
 
 
 
Product name,      Writing, selling,  Number of             Exercise  Type, e.g.      Expiry  Option money 
 e.g. call option   purchasing         securities to which   price     American,       date    paid/received 
                    varying etc.       the option relates              European etc.           per unit (Note 5) 
                                       (Note 7) 
-----------------  -----------------  --------------------  --------  --------------  ------  ------------------ 
N/A 
-----------------  -----------------  --------------------  --------  --------------  ------  ------------------ 
 
 
   (ii) Exercising 
 
 
 
 
Product name,      Number of securities  Exercise price per 
 e.g. call option                           unit (Note 5) 
-----------------  --------------------  ------------------ 
N/A 
-----------------  --------------------  ------------------ 
 
 
   (d) Other dealings (including transactions in respect of new securities) 
(Note 4) 
 
 
 
 
Nature of transaction  Details       Price per unit 
 (Note 8)                        (if applicable) (Note 5) 
---------------------  -------  ------------------------- 
N/A 
---------------------  -------  ------------------------- 
 
 
   4. OTHER INFORMATION 
 
   Agreements, arrangements or understandings relating to options or 
derivatives 
 
 
 
 
Full details of any agreement, arrangement or understanding 
 between the person disclosing and any other person 
 relating to the voting rights of any relevant securities 
 under any option referred to on this form or relating 
 to the voting rights or future acquisition or disposal 
 of any relevant securities to which any derivative 
 referred to on this form is referenced. If none, this 
 should be stated. 
----------------------------------------------------------- 
N/A 
----------------------------------------------------------- 
 
 
 
 
 
 
Is a Supplemental Form 8 attached? (Note 9)                       NO 
-------------------------------------------------------  -------------------- 
Date of disclosure                                       08(th) November 2019 
-------------------------------------------------------  -------------------- 
Contact name                                                Lionel Colaco 
-------------------------------------------------------  -------------------- 
Telephone number                                                 020 33956098 
-------------------------------------------------------  -------------------- 
If a connected EFM, name of offeree/offeror with which   N/A 
 connected 
-------------------------------------------------------  -------------------- 
If a connected EFM, state nature of connection (Note     N/A 
 10) 
-------------------------------------------------------  -------------------- 
 
 
 
 
 
 

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN PLC
10:35aDAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
09:49aALLERGAN : Form 8.3 -
DJ
11/21DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
11/21ALLERGAN : Form 8.3 -
DJ
11/20DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
11/20ALLERGAN : Form 8.3 -
DJ
11/20ABBVIE : Form 8.3 -
AQ
11/19DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
11/19ALLERGAN : Form 8.3 -
DJ
11/19FDA Accepts Avastin Biosimilar BLA From Biogen, Samsung BioLogics Venture
DJ
More news